New Esophageal Cancer Indication for Pembrolizumab.

Abstract

Pembrolizumab (Keytruda) is now approved for patients with recurrent, locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express programmed death ligand 1. A special diagnostic test to determine patient eligibility has also been approved.The drug carries the same ad